ERBB2 and breast cancer: The characteristics of the patients in the present series differ from those reported in other publications on PDB, particularly because 87.1% of the patients were diagnosed and treated after 2010, reflecting the major changes that have occurred in breast cancer management, including sentinel lymph node biopsy, oncoplastic surgery and the use of HER2-targeted therapies.